Against the background of the upsurge in interest in Alzheimer's disease driven by the recent controversial US approval of Biogen's Aduhelm, Muna Therapeutics has launched with an impressive $73m series A financing supported by a global syndicate of big name investors who are backing the Danish biotech's approach to slowing or stopping neurodegenerative diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?